{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.0","upperLimit":"51.6","value":"46.2"},{"groupId":"OG001","lowerLimit":"34.9","upperLimit":"49.8","value":"42.2"}]}],"title":"Response Rate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"96.0","upperLimit":"99.2","value":"98.1"},{"groupId":"OG001","lowerLimit":"90.0","upperLimit":"97.3","value":"94.4"}]}],"title":"Disease Control Rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD. Response Rate = (CR+PR)/Participants in Arm\\*100. Disease Control Rate=(CR+PR+SD)/Number of Participants in Arm\\*100.","dispersionType":"95% Confidence Interval","groups":[{"description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care","id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed"},{"description":"pemetrexed + cisplatin followed by placebo plus best supportive care","id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Date of randomization to date of measured PD (up to 19.3 months)","title":"Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off","type":"SECONDARY","unitOfMeasure":"percentage of participants"}